TIDMMXCT TIDMTTM

RNS Number : 3554Y

MaxCyte, Inc.

02 January 2024

MaxCyte, Inc.

("MaxCyte" or the "Company")

Total Voting Rights

ROCKVILLE, MD, January 2, 2024 - MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications , announces that pursuant to its block admission facility, since 30 November 2023 it has issued 251,799 of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options.

Total voting rights

As at 31 December 2023, the total issued stock capital of the Company following the recent issue of the new Common Stock is 103,961,670 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

For further information, please contact:

 
  MaxCyte Contacts: 
   US IR Adviser                                    +1 415-937-5400 
   Gilmartin Group                                  ir@maxcyte.com 
   David Deuchler, CFA 
  Nominated Adviser and Joint Corporate Broker 
   Panmure Gordon 
   Emma Earl / Freddy Crossley 
   Corporate Broking 
   Rupert Dearden                                   +44 (0)20 7886 2500 
 
    UK IR Adviser                                  +44 (0)203 709 5700 
    ICR Consilium                                  maxcyte@consilium-comms.com 
    Mary-Jane Elliott 
    Chris Welsh

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT(TM) platform, which is based on our Flow Electroporation(R) technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx(TM), STx(TM), GTx(TM) and VLx (TM); a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical, and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRQKBBBCBKKKDK

(END) Dow Jones Newswires

January 02, 2024 04:23 ET (09:23 GMT)

Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Maxcyte Charts.
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Maxcyte Charts.